['type 1 diabetes']
["mylan's insulin glargine", 'lantus®']

        Inclusion Criteria:

          -  Patients with an established diagnosis of T1DM per ADA 2014 criteria

          -  Body mass index (BMI) of 18.5 to 35 kg/m2 at screening (both values inclusive).

          -  Glycosylated hemoglobin (HbA1c) ≤9.5% at screening.

          -  Hemoglobin ≥9.0 g/dL at screening.

        Exclusion Criteria:

          -  History of hypersensitivity to any of the active or inactive ingredients of the
             insulin/insulin analogue preparations used in the trial, OR history of significant
             allergic drug reactions.

          -  History of use of animal insulin within the last 3 years or use of biosimilar insulin
             glargine at any time prior.

          -  History of use of a regular immunomodulator therapy in the 1 year prior to screening.

          -  History of ≥2 episodes of severe hypoglycemia within the 6 months before screening or
             history of hypoglycemia unawareness (a sample questionnaire is provided in Appendix
             I), as judged by the investigator.

          -  History of ≥1 episodes of diabetic ketoacidosis or emergency room visits for
             uncontrolled diabetes leading to hospitalization within the 6 months prior to
             screening.

          -  Serological evidence of human immunodeficiency virus (HIV), hepatitis B (HbSAg) or
             hepatitis C (HCVAb) antibodies at screening.

          -  History of drug or alcohol dependence or abuse during the 1 year prior to screening.
      